Figure 3
Five-year probabilities of LFS after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations adjusted for age, disease status at transplantation, graft type, and transplantation period.
Five-year probabilities of LFS after T cell–replete, ATG-containing, and alemtuzumab-containing transplantations adjusted for age, disease status at transplantation, graft type, and transplantation period.
